Denali Stock Falls as Partner Takeda Ends Collaboration Deal

Takeda has exited the DNL593 partnership, leaving Denali Therapeutics (DNLI) as sole controller and funder of the program as it advances studies and targets a 2026 data readout. The change prompted a decline in DNLI shares and raises execution and funding risk for Denali, potentially pressuring near-term cash needs and valuation.

Analysis

Takeda has exited the DNL593 partnership, leaving Denali Therapeutics (DNLI) as sole controller and funder of the program as it advances studies and targets a 2026 data readout. The change prompted a decline in DNLI shares and raises execution and funding risk for Denali, potentially pressuring near-term cash needs and valuation.